Aptahem is active within biotechnology. The company conducts research and development of aptamer-based pharmaceuticals for the treatment of acute conditions caused by sepsis, blockage of blood vessels, stroke, and heart failure. Through early treatment, the pharmaceutical is intended to prevent damage to organs and tissue. A large part of the research is carried out in collaboration with partners within the industry. The company was founded in 2014 and is based in Malmö.

Quotes for Aptahem AB

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Mikael Lindstam

Chairperson of the Board

  • Bert Junno

Board

  • Åsa Kornfeld
  • Cristina Glad
  • Jan Nilsson
  • Johan Lindh
  • Theresa Comiskey Olsen

Videos

Largest Owners

Name Capital % Votes % Date
Ivar Nordqvist 13,47 13,47 2023-12-27
Avanza Pension 6,95 6,95 2023-12-27
Nordnet Pensionsförsäkring 4,18 4,18 2023-12-27
Gunvald Berger 2,30 2,30 2023-12-27
Tuvedalen Ltd 2,03 2,03 2024-02-07
Christian Pettersson 1,42 1,42 2023-12-27
AB Svedala Finans 1,15 1,15 2023-12-27
Adel Hanna 0,97 0,97 2023-12-27
Nicklas Johansson 0,91 0,91 2023-12-27
Viparium AB 0,88 0,88 2023-12-27
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream